secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmonx Corp (LUNG)
CIK:        0001127537
Form:       8-K
Filed at:   2022-08-02T23:59:59+00:00
Accession:  0001127537-22-000033
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmonx Q2 revenue $14.0M (+14% YoY); net loss $14.6M; reaffirms FY outlook
---------------------------------------------------------------------------

- Revenue $14.0M, up 14% YoY (19% constant currency); U.S. revenue $8.6M (+31%).
- Net loss $14.6M ($0.40/share) vs $13.0M ($0.36/share) in Q2 2021.
- Gross margin improved to 75% from 74% due to production efficiencies.
- Added 18 new U.S. treatment centers (total 248); cash $166.8M.
- FY2022 revenue guidance reaffirmed $55M-$60M; operating expenses $100M-$105M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1127537/000112753722000033/0001127537-22-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1127537/000112753722000033/lung-20220802.htm
  HTML page:      https://secwatch.observer/filing/0001127537-22-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer